PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.01
D/E ratio near Healthcare median of 0.01. Philip Fisher would examine if industry-standard leverage is optimal for the business model.
3.31
Dangerously high net debt exceeding 1.5x Healthcare median of 1.74. Michael Burry would check for debt covenant compliance and refinancing risks.
No Data
No Data available this quarter, please select a different quarter.
1.37
Current ratio 50-75% of Healthcare median of 2.37. Martin Whitman would look for hidden assets or working capital optimization.
No Data
No Data available this quarter, please select a different quarter.